QLGN - Qualigen Therapeutics GAAP EPS of -$0.69 revenue of $1.62M

2023-08-15 09:10:45 ET

• Qualigen Therapeutics press release ( NASDAQ: QLGN ): Q2 GAAP EPS of -$0.69.
• Revenue of $1.62M (+13.3% Y/Y).

• Sales and marketing expenses were approximately $0.2 million for the quarter ended June 30, 2023, a decrease of $0.1 million or 45%, compared to the quarter ended June 30, 2022, primarily due to the January 2023 reduction in force.

• For the quarter ended June 30, 2023, the Company reported a net loss attributable to Qualigen Therapeutics, Inc. of approximately $3.5 million, or $0.69 per common share basic and diluted, compared to a net loss of approximately $4.1 million, or $1.12 per common share basic and diluted, for the corresponding period in 2022.

For further details see: